APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-tumor Drug

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.

Selected research

Market Analysis & Forecast

Global Anti-tumor Drug Market Analysis and Forecast 2026-2032

21 December 2025205 pages

Choose your research edition.

Industry ResearchAnti-tumor Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-tumor Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Anti-tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-tumor Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-tumor Drug Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.

In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.

United States is the largest market, followed by Japan, and Europe.

Read the full market overview

Report Includes

This report presents an overview of global market for Anti-tumor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-tumor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-tumor Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-tumor Drug revenue, projected growth trends, production technology, application and end-user industry.

Anti-tumor Drug Segment by Company

Roche

Novartis

Celgene

Bristol-Myers Squibb

Amgen

Johnson & Johnson

Pfizer

Takeda

Eli Lilly

AstraZeneca

Astellas

Merck & Co

Sanofi

Bayer

Biogen Idec

Eisai

Teva

Otsuka

Anti-tumor Drug Segment by Type

Cytotoxic Drugs

Non-cytotoxic Drugs

Anti-tumor Drug Segment by Application

Alkylating Agents

Anti-Metabolism Drugs

Platinum Antineoplastic Agents

Anthracycline Antitumor Drugs

Microtubule Stabilizer

Endocrine Therapy Drugs

Immunotherapy Drugs

Gene Therapy Drugs

Targeted Antineoplastic Drugs

Anti-tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti-tumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti-tumor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-tumor Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cytotoxic Drugs Major Player Table 3. Non-cytotoxic Drugs Major Player Table 4. Global Anti-tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Alkylating Agents Major Player Table 6. Anti-Metabolism Drugs Major Player Table 7. Platinum Antineoplastic Agents Major Player Table 8. Anthracycline Antitumor Drugs Major Player Table 9. Microtubule Stabilizer Major Player Table 10. Endocrine Therapy Drugs Major Player Table 11. Immunotherapy Drugs Major Player Table 12. Gene Therapy Drugs Major Player Table 13. Targeted Antineoplastic Drugs Major Player Table 14. Anti-tumor Drug Industry Trends Table 15. Anti-tumor Drug Industry Drivers Table 16. Anti-tumor Drug Industry Opportunities and Challenges Table 17. Anti-tumor Drug Industry Restraints Table 18. Global Anti-tumor Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Anti-tumor Drug Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Anti-tumor Drug Market Share by Region (2021-2026) Table 21. Global Anti-tumor Drug Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Anti-tumor Drug Market Share by Region (2027-2032) Table 23. Global Anti-tumor Drug Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Anti-tumor Drug Revenue Market Share by Players (2021-2026) Table 25. Global Anti-tumor Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Anti-tumor Drug Key Players Headquarters & Area Served Table 27. Global Anti-tumor Drug Players, Product Type & Application Table 28. Global Anti-tumor Drug Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Anti-tumor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Anti-tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Anti-tumor Drug Revenue Market Share by Type (2021-2026) Table 35. Global Anti-tumor Drug Revenue Market Share by Type (2027-2032) Table 36. Global Anti-tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Anti-tumor Drug Revenue Market Share by Application (2021-2026) Table 40. Global Anti-tumor Drug Revenue Market Share by Application (2027-2032) Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche Anti-tumor Drug Product Portfolio Table 45. Roche Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Anti-tumor Drug Product Portfolio Table 50. Novartis Recent Development Table 51. Celgene Company Information Table 52. Celgene Business Overview Table 53. Celgene Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Celgene Anti-tumor Drug Product Portfolio Table 55. Celgene Recent Development Table 56. Bristol-Myers Squibb Company Information Table 57. Bristol-Myers Squibb Business Overview Table 58. Bristol-Myers Squibb Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Bristol-Myers Squibb Anti-tumor Drug Product Portfolio Table 60. Bristol-Myers Squibb Recent Development Table 61. Amgen Company Information Table 62. Amgen Business Overview Table 63. Amgen Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Amgen Anti-tumor Drug Product Portfolio Table 65. Amgen Recent Development Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Johnson & Johnson Anti-tumor Drug Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Anti-tumor Drug Product Portfolio Table 75. Pfizer Recent Development Table 76. Takeda Company Information Table 77. Takeda Business Overview Table 78. Takeda Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Takeda Anti-tumor Drug Product Portfolio Table 80. Takeda Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eli Lilly Anti-tumor Drug Product Portfolio Table 85. Eli Lilly Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Anti-tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. AstraZeneca Anti-tumor Drug Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Astellas Company Information Table 92. Astellas Business Overview Table 93. Astellas Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Astellas Anti-tumor Drug Product Portfolio Table 95. Astellas Recent Development Table 96. Merck & Co Company Information Table 97. Merck & Co Business Overview Table 98. Merck & Co Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Merck & Co Anti-tumor Drug Product Portfolio Table 100. Merck & Co Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Sanofi Anti-tumor Drug Product Portfolio Table 105. Sanofi Recent Development Table 106. Bayer Company Information Table 107. Bayer Business Overview Table 108. Bayer Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Bayer Anti-tumor Drug Product Portfolio Table 110. Bayer Recent Development Table 111. Biogen Idec Company Information Table 112. Biogen Idec Business Overview Table 113. Biogen Idec Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Biogen Idec Anti-tumor Drug Product Portfolio Table 115. Biogen Idec Recent Development Table 116. Eisai Company Information Table 117. Eisai Business Overview Table 118. Eisai Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Eisai Anti-tumor Drug Product Portfolio Table 120. Eisai Recent Development Table 121. Teva Company Information Table 122. Teva Business Overview Table 123. Teva Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. Teva Anti-tumor Drug Product Portfolio Table 125. Teva Recent Development Table 126. Otsuka Company Information Table 127. Otsuka Business Overview Table 128. Otsuka Anti-tumor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 129. Otsuka Anti-tumor Drug Product Portfolio Table 130. Otsuka Recent Development Table 131. North America Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. North America Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. North America Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Anti-tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 137. North America Anti-tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 138. Europe Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 139. Europe Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 140. Europe Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. Europe Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. Europe Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Anti-tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 144. Europe Anti-tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 145. China Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 146. China Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 147. China Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 148. China Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Asia Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Anti-tumor Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Asia Anti-tumor Drug Revenue by Region (US$ Million) & (2021-2026) Table 155. Asia Anti-tumor Drug Revenue by Region (US$ Million) & (2027-2032) Table 156. SAMEA Anti-tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 157. SAMEA Anti-tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 158. SAMEA Anti-tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 159. SAMEA Anti-tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 160. SAMEA Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. SAMEA Anti-tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 162. SAMEA Anti-tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Anti-tumor Drug Image Figure 2. Global Anti-tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cytotoxic Drugs Image Figure 5. Non-cytotoxic Drugs Image Figure 6. Global Anti-tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Alkylating Agents Image Figure 9. Anti-Metabolism Drugs Image Figure 10. Platinum Antineoplastic Agents Image Figure 11. Anthracycline Antitumor Drugs Image Figure 12. Microtubule Stabilizer Image Figure 13. Endocrine Therapy Drugs Image Figure 14. Immunotherapy Drugs Image Figure 15. Gene Therapy Drugs Image Figure 16. Targeted Antineoplastic Drugs Image Figure 17. Global Anti-tumor Drug Market Size (US$ Million) & (2021-2032) Figure 18. Global Anti-tumor Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Anti-tumor Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Anti-tumor Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Anti-tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Anti-tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-tumor Drug Revenue Market Share by Type (2021-2032) Figure 25. Global Anti-tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Anti-tumor Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Anti-tumor Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Anti-tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Anti-tumor Drug Revenue Share by Type (2021-2032) Figure 30. North America Anti-tumor Drug Revenue Share by Application (2021-2032) Figure 31. North America Anti-tumor Drug Revenue Share by Country (2021-2032) Figure 32. United States Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Anti-tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Anti-tumor Drug Revenue Share by Type (2021-2032) Figure 37. Europe Anti-tumor Drug Revenue Share by Application (2021-2032) Figure 38. Europe Anti-tumor Drug Revenue Share by Country (2021-2032) Figure 39. Germany Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Anti-tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Anti-tumor Drug Revenue Share by Type (2021-2032) Figure 49. China Anti-tumor Drug Revenue Share by Application (2021-2032) Figure 50. Asia Anti-tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Anti-tumor Drug Revenue Share by Type (2021-2032) Figure 52. Asia Anti-tumor Drug Revenue Share by Application (2021-2032) Figure 53. Asia Anti-tumor Drug Revenue Share by Region (2021-2032) Figure 54. Japan Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Anti-tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Anti-tumor Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Anti-tumor Drug Revenue Share by Application (2021-2032) Figure 63. SAMEA Anti-tumor Drug Revenue Share by Country (2021-2032) Figure 64. Brazil Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Anti-tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Cytotoxic Drugs
  • Non-cytotoxic Drugs
Applications
  • Alkylating Agents
  • Anti-Metabolism Drugs
  • Platinum Antineoplastic Agents
  • Anthracycline Antitumor Drugs
  • Microtubule Stabilizer
  • Endocrine Therapy Drugs
  • Immunotherapy Drugs
  • Gene Therapy Drugs
  • Targeted Antineoplastic Drugs
Companies covered
  • Roche
  • Novartis
  • Celgene
  • Bristol-Myers Squibb
  • Amgen
  • Johnson & Johnson
  • Pfizer
  • Takeda
  • Eli Lilly
  • AstraZeneca
  • Astellas
  • Merck & Co
  • Sanofi
  • Bayer
  • Biogen Idec
  • Eisai
  • Teva
  • Otsuka

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-tumor Drug Market by Type
  3. 1.2.1 Global Anti-tumor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cytotoxic Drugs
  5. 1.2.3 Non-cytotoxic Drugs
  6. 1.3 Anti-tumor Drug Market by Application
  7. 1.3.1 Global Anti-tumor Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Alkylating Agents
  9. 1.3.3 Anti-Metabolism Drugs
  10. 1.3.4 Platinum Antineoplastic Agents
  11. 1.3.5 Anthracycline Antitumor Drugs
  12. 1.3.6 Microtubule Stabilizer
  13. 1.3.7 Endocrine Therapy Drugs
  14. 1.3.8 Immunotherapy Drugs
  15. 1.3.9 Gene Therapy Drugs
  16. 1.3.10 Targeted Antineoplastic Drugs
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Anti-tumor Drug Market Dynamics
  1. 2.1 Anti-tumor Drug Industry Trends
  2. 2.2 Anti-tumor Drug Industry Drivers
  3. 2.3 Anti-tumor Drug Industry Opportunities and Challenges
  4. 2.4 Anti-tumor Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti-tumor Drug Market Perspective (2021-2032)
  2. 3.2 Global Anti-tumor Drug Growth Trends by Region
  3. 3.2.1 Global Anti-tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-tumor Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti-tumor Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti-tumor Drug Revenue by Players
  2. 4.1.1 Global Anti-tumor Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti-tumor Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-tumor Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti-tumor Drug Key Players Headquarters & Area Served
  7. 4.4 Global Anti-tumor Drug Players, Product Type & Application
  8. 4.5 Global Anti-tumor Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti-tumor Drug Market CR5 and HHI
  11. 4.6.3 2025 Anti-tumor Drug Tier 1, Tier 2, and Tier 3
5 Anti-tumor Drug Market Size by Type
  1. 5.1 Global Anti-tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti-tumor Drug Revenue by Type (2021-2032)
  3. 5.3 Global Anti-tumor Drug Revenue Market Share by Type (2021-2032)
6 Anti-tumor Drug Market Size by Application
  1. 6.1 Global Anti-tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti-tumor Drug Revenue by Application (2021-2032)
  3. 6.3 Global Anti-tumor Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche Anti-tumor Drug Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Anti-tumor Drug Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Celgene
  14. 7.3.1 Celgene Company Information
  15. 7.3.2 Celgene Business Overview
  16. 7.3.3 Celgene Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Celgene Anti-tumor Drug Product Portfolio
  18. 7.3.5 Celgene Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Anti-tumor Drug Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Amgen
  26. 7.5.1 Amgen Company Information
  27. 7.5.2 Amgen Business Overview
  28. 7.5.3 Amgen Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Anti-tumor Drug Product Portfolio
  30. 7.5.5 Amgen Recent Developments
  31. 7.6 Johnson & Johnson
  32. 7.6.1 Johnson & Johnson Company Information
  33. 7.6.2 Johnson & Johnson Business Overview
  34. 7.6.3 Johnson & Johnson Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Johnson & Johnson Anti-tumor Drug Product Portfolio
  36. 7.6.5 Johnson & Johnson Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Anti-tumor Drug Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Takeda
  44. 7.8.1 Takeda Company Information
  45. 7.8.2 Takeda Business Overview
  46. 7.8.3 Takeda Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Takeda Anti-tumor Drug Product Portfolio
  48. 7.8.5 Takeda Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Anti-tumor Drug Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Anti-tumor Drug Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 Astellas
  62. 7.11.1 Astellas Company Information
  63. 7.11.2 Astellas Business Overview
  64. 7.11.3 Astellas Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Astellas Anti-tumor Drug Product Portfolio
  66. 7.11.5 Astellas Recent Developments
  67. 7.12 Merck & Co
  68. 7.12.1 Merck & Co Company Information
  69. 7.12.2 Merck & Co Business Overview
  70. 7.12.3 Merck & Co Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Merck & Co Anti-tumor Drug Product Portfolio
  72. 7.12.5 Merck & Co Recent Developments
  73. 7.13 Sanofi
  74. 7.13.1 Sanofi Company Information
  75. 7.13.2 Sanofi Business Overview
  76. 7.13.3 Sanofi Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Sanofi Anti-tumor Drug Product Portfolio
  78. 7.13.5 Sanofi Recent Developments
  79. 7.14 Bayer
  80. 7.14.1 Bayer Company Information
  81. 7.14.2 Bayer Business Overview
  82. 7.14.3 Bayer Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Bayer Anti-tumor Drug Product Portfolio
  84. 7.14.5 Bayer Recent Developments
  85. 7.15 Biogen Idec
  86. 7.15.1 Biogen Idec Company Information
  87. 7.15.2 Biogen Idec Business Overview
  88. 7.15.3 Biogen Idec Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Biogen Idec Anti-tumor Drug Product Portfolio
  90. 7.15.5 Biogen Idec Recent Developments
  91. 7.16 Eisai
  92. 7.16.1 Eisai Company Information
  93. 7.16.2 Eisai Business Overview
  94. 7.16.3 Eisai Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Eisai Anti-tumor Drug Product Portfolio
  96. 7.16.5 Eisai Recent Developments
  97. 7.17 Teva
  98. 7.17.1 Teva Company Information
  99. 7.17.2 Teva Business Overview
  100. 7.17.3 Teva Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Teva Anti-tumor Drug Product Portfolio
  102. 7.17.5 Teva Recent Developments
  103. 7.18 Otsuka
  104. 7.18.1 Otsuka Company Information
  105. 7.18.2 Otsuka Business Overview
  106. 7.18.3 Otsuka Anti-tumor Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Otsuka Anti-tumor Drug Product Portfolio
  108. 7.18.5 Otsuka Recent Developments
8 North America
  1. 8.1 North America Anti-tumor Drug Revenue (2021-2032)
  2. 8.2 North America Anti-tumor Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti-tumor Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti-tumor Drug Revenue by Type (2027-2032)
  5. 8.3 North America Anti-tumor Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti-tumor Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti-tumor Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti-tumor Drug Revenue by Application (2027-2032)
  9. 8.5 North America Anti-tumor Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti-tumor Drug Revenue by Country
  11. 8.6.1 North America Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti-tumor Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti-tumor Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Anti-tumor Drug Revenue (2021-2032)
  2. 9.2 Europe Anti-tumor Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti-tumor Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti-tumor Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Anti-tumor Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti-tumor Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti-tumor Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti-tumor Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Anti-tumor Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti-tumor Drug Revenue by Country
  11. 9.6.1 Europe Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti-tumor Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti-tumor Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Anti-tumor Drug Revenue (2021-2032)
  2. 10.2 China Anti-tumor Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Anti-tumor Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Anti-tumor Drug Revenue by Type (2027-2032)
  5. 10.3 China Anti-tumor Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Anti-tumor Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Anti-tumor Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Anti-tumor Drug Revenue by Application (2027-2032)
  9. 10.5 China Anti-tumor Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-tumor Drug Revenue (2021-2032)
  2. 11.2 Asia Anti-tumor Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti-tumor Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti-tumor Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Anti-tumor Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti-tumor Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti-tumor Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti-tumor Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Anti-tumor Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti-tumor Drug Revenue by Country
  11. 11.6.1 Asia Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti-tumor Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti-tumor Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-tumor Drug Revenue (2021-2032)
  2. 12.2 SAMEA Anti-tumor Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti-tumor Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti-tumor Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti-tumor Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti-tumor Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti-tumor Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti-tumor Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti-tumor Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti-tumor Drug Revenue by Country
  11. 12.6.1 SAMEA Anti-tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti-tumor Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti-tumor Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst